N. Booher, Robert Hatch, Harold M. Dolinski, Brian Nguyen, Thi Harmonay, Lauren Al-Assaad, Ali-Samer Ayers, Mark Nebozhyn, Michael Loboda, Andrey A. Hirsch, Heather Zhang, Theresa Shi, Bin E. Merkel, Carrie H. Angagaw, Minilik Wang, Yaolin J. Long, Brian Q. Lennon, Xianlu Miselis, Nathan Pucci, Vincenzo W. Monahan, James Lee, Junghoon Georgieva Kondic, Anna Kyung Im, Eun Mauro, David Blanchard, Rebecca Gilliland, Gary E. Fawell, Stephen Zawel, Leigh G. Schuller, Alwin Strack, Peter Summary of Bliss scores and sensitivity to dinaciclib, navitoclax and combination treatment. 1<p>Synergy analysis after 18 hr treatment. vBliss: synergy (>0.1), additive (0.1–0.05). neutral (<0.05-0), antagonistic (<0).</p>2<p>Percent viability after 18 hour treatment with 100 nM dinaciclib, 1 µM navitoclax or the combination.</p>3<p>Information source. Cancer Cell Line Encyclopedia converted from log 2 to log10.</p><p>Summary of Bliss scores and sensitivity to dinaciclib, navitoclax and combination treatment.</p> MCL 1;antiapoptotic BCL 2 family member MCL 1;MCL 1 amplification;BCL 2 family member inhibitors;cdk;mechanism;dinaciclib antitumor response;abt;cell cycle progression 2014-10-07
    https://plos.figshare.com/articles/dataset/_Summary_of_Bliss_scores_and_sensitivity_to_dinaciclib_navitoclax_and_combination_treatment_/1196741
10.1371/journal.pone.0108371.t001